Healthcare

Share

Facebook Twitter Linkedin

Chimeric Therapeutics Ltd (ASX:CHM)

0.014 AUD

0.000 0.000%

Last Updated at: 2024-10-09T23:00:00Z

Risk Disclaimer CHM chart by TradingView

Back to ASX:CHM

Risk Disclaimer CHM chart by TradingView

Sponsored Reports

Loading...

Previous Close (in AUD)	0.014
Change	0.000 0.000%
52 W H/L (in AUD)	0.047/0.013
EBITDA (in AUD)	-11.3M
PE Ratio	--
Volume	--
Diluted Eps TTM	-0.02

Total Assets (in AUD)	15.273M
Total Liabilities (in AUD)	12.803M
Revenue TTM (in AUD)	7.458M
Cash (in AUD)	3.053M
Market Cap (in AUD)	12.672 M
Revenue Per Share TTM	0.011
Gross Profit TTM (in AUD)	4.506M

Summary

---

Income Statement

Balance Sheet

Change in Cash

Operating Cash

Chimeric Therapeutics Ltd

Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies in oncology in Australia. The company develops CHM 0201 (core NK platform) that is in phase I clinical trial for treating solid tumors and hematological malignancies; and CHM 1101 (CLTX CAR T), which is in phase I clinical trial for treating patients with MMP2+ recurrent or progressive glioblastoma. It is also developing CHM 0301 for blood cancers; CHM 1301 (CLTX CAR NK) and CHM 2301 (CDH17 CAR NK) for solid tumors; CHM 1101 (CLTX CAR T) for melanoma, colorectal, and prostate; and CHM 2101 (CDH17 CAR T) for neuroendocrine, colorectal, pancreatic, and gastric. The company was incorporated in 2020 and is based in Carlton, Australia.

62 Lygon Street, Carlton, VIC, Australia, 3053

61 3 9824 5254

https://www.chimerictherapeutics.com

Key Executives

Sr. No.	Name	Title	Year Born
1.	Ms. Jennifer Chow	CEO, MD & Director	NA
2.	Mr. Eliot Bourk	Chief Bus. Officer & Head of External Innovation	NA
3.	Dr. Li Ren	VP of Technical Operations	NA
4.	Mr. Kelly R. Thornburg	VP & Head of Quality	1963
5.	Mr. Jason B. Litten M.D.	Chief Medical Officer	1974
6.	Mr. Phillip Hains B Bus, C.A., CA, M.B.A., MBA	Sec.	1961
7.	Mr. Nathan Jong C.A.	Company Sec.	NA
8.	Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD	Founder & Executive Chairman	1956
9.	Mr. Eliot Bourk	Chief Business Officer & Head of External Innovation	NA
10.	Mr. Phillip Allen Hains BBus(Acc), C.A., M.B.A.	CFO, Joint Company Secretary & Director	1959

Peers

Sector: Healthcare

Industry: Biotechnology

Company	Change (AUD)	Price (AUD)	Trailing PE(x)	Forward PE(x)	Price Sales TTM(x)	Price to Book Value(x)	Enterprise Value to Revenue(x)	Enterprise Value to EBITDA(x)
CSL CSL Ltd	+1.080 0.367%	293.56	36.670	31.949	9.623	5.594	7.328	22.744
TLX Telix Pharmaceuticals Ltd	-0.060 0.284%	21.14	139.200	21.008	10.714	17.174	10.739	93.760
CU6 Clarity Pharmaceuticals Ltd	-0.230 3.230%	7.01	0.000	0.000	213.080	17.240	0.000	-0.779
NEU Neuren Pharmaceuticals Ltd	-0.270 2.055%	13.03	14.130	35.211	8.840	5.319	6.770	8.824

• Income Statement
• Balance Sheet
• Cash Flow

Income Statement

(Currency in AUD)

Breakdown	30-06-2023	30-06-2022	30-06-2021	30-06-2020
Income Before Tax	-25.408M	-14.46M	-15.114M	-0.064M
Minority Interest	-	-	-	-
Net Income	-25.5M	-14.624M	-15.114M	-0.064M
Selling General Administrative	14.881M	8.731M	5.823M	0.064M
Gross Profit	-	-	0.003M	-
Reconciled Depreciation	0.965M	0.95M	0.003M	-
Ebit	-24.981M	-13.818M	-15.108M	-0.154M
Ebitda	-23.668M	-12.868M	-15.105M	-
Depreciation And Amortization	-	0.95M	0.003M	-
Operating Income	-25.408M	-13.818M	-15.108M	-0.064M
Other Operating Expenses	-	17.19M	14.847M	3.499M
Interest Expense	0.851M	0.64M	0.006M	0M
Tax Provision	0.093M	0.164M	0M	0M
Interest Income	0.028M	0.013M	0.003M	-
Net Interest Income	-0.746M	-0.627M	-0.006M	-
Income Tax Expense	0.093M	0.164M	-0.258M	-
Total Revenue	0M	0M	0.003M	0M
Total Operating Expenses	-	17.19M	14.847M	-
Cost Of Revenue	-	-	-	-
Total Other Income Expense Net	4.826M	3.357M	-0.264M	-
Net Income From Continuing Ops	-25.5M	-14.624M	-15.114M	-
Net Income Applicable To Common Shares	-25.917M	-15.898M	-15.114M	-0.154M

Balance Sheet

(Currency in AUD)

Breakdown	30-06-2024	30-06-2023	30-06-2022	30-06-2021	30-06-2020
Total Assets	15.273M	22.492M	34.88M	36.505M	0M
Intangible Assets	-	12.979M	13.653M	13.826M	-
Other Current Assets	0.083M	0.331M	0.131M	0.231M	-
Total Liab	12.803M	16.415M	9.173M	11.374M	0.064M
Total Stockholder Equity	2.47M	6.077M	25.706M	25.131M	-0.064M
Other Current Liab	6.896M	3.519M	4.317M	5.317M	-
Common Stock	63.511M	53.929M	51.808M	37.367M	0M
Capital Stock	-	53.929M	51.808M	37.367M	-
Retained Earnings	-66.56M	-56.781M	-29.589M	-15.178M	-0.064M
Good Will	-	-	-	-	-
Other Assets	-	-	0.04M	-	-
Cash	3.053M	2.363M	18.382M	22.41M	0M
Cash And Equivalents	-	-	18.382M	22.41M	-
Total Current Liabilities	10.097M	14.693M	9.021M	7.355M	0.064M
Current Deferred Revenue	-	-	-	-	-
Net Debt	-3.053M	-	-18.382M	-22.41M	-
Short Term Debt	-	-	0M	0M	0.034M
Short Long Term Debt	-	-	-	-	-
Short Long Term Debt Total	-	-	-	3.683M	-
Other Stockholder Equity	-	8.512M	-0.879M	2.942M	-
Property Plant Equipment	-	0.006M	0.016M	0.014M	-
Total Current Assets	3.222M	9.351M	21.171M	22.665M	0M
Long Term Investments	-	0.04M	0.04M	-	-
Short Term Investments	-	-	-	-	-
Net Receivables	0.087M	3.651M	3.54M	0.024M	-
Long Term Debt	-	-	0M	3.683M	-
Inventory	-	-	-0.882M	-	-
Accounts Payable	3.201M	7.407M	4.704M	2.038M	-
Accumulated Other Comprehensive Income	5.519M	-	4.367M	2.942M	-
Non Currrent Assets Other	12.05M	-	-	-	-
Non Current Assets Total	12.051M	13.024M	13.709M	13.84M	-
Capital Lease Obligations	-	-	-	-	-
Long Term Debt Total	-	-	0M	3.683M	0M

Cash Flow

(Currency in AUD)

Breakdown	30-06-2023	30-06-2022	30-06-2021	30-06-2020
Investments	-0.112M	-0.04M	-0.04M	-0.04M
Total Cashflows From Investing Activities	-0.112M	-0.578M	-5.307M	-5.307M
Total Cash From Financing Activities	0.253M	9.504M	36.541M	0.082M
Net Income	-25.917M	-15.898M	-15.114M	-0.154M
Change In Cash	-16.019M	-4.029M	22.41M	0M
Begin Period Cash Flow	18.382M	22.41M	0M	-
End Period Cash Flow	2.363M	18.382M	22.41M	0M
Total Cash From Operating Activities	-16.306M	-13.153M	-8.833M	-0.082M
Depreciation	0.965M	0.95M	0.847M	0.847M
Other Cashflows From Investing Activities	0M	0.013M	0.003M	0.003M
Dividends Paid	-	-	-	-
Change To Inventory	-	-	-	-
Sale Purchase Of Stock	2.578M	-1.309M	-2.715M	0M
Other Cashflows From Financing Activities	-0.099M	-0.565M	0.848M	-2.725M
Capital Expenditures	0.112M	0.538M	5.307M	0.016M
Change In Working Capital	3.527M	-0.003M	-	-
Other Non Cash Items	-	-	-	-
Free Cash Flow	-16.418M	-0.538M	-5.307M	-

No data found

Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).

• Top Gainer
• Top Loser